Overview

Investing.com’s ProPicks AI stock‑picker, launched in November 2023, has delivered a cumulative return of +222.88% (rounded to +223%) to date, outperforming the S&P 500 by +149.5% over the same period.

June Performance

In June, AI‑selected equities posted strong single‑month gains, notably:

  • Amneal Pharmaceuticals (NASDAQGS:AMRX) +33.57%
  • Onto Innovation (NYSE:ONTO) +26.67%
  • Molina Healthcare (NYSE:MOH) +25.37%
  • Veeco Instruments (NASDAQGS:VECO) +23.93%
  • Allegro MicroSystems (NASDAQ:ALGM) +22.83%

The article also cites more than 25 other stocks achieving double‑digit rallies during the month.

Long‑Term Winners

Stocks retained in the portfolio have generated multi‑year upside, including:

  • Consensus Cloud Solutions (NASDAQGS:CCSI) +71.91%
  • Molina Healthcare +69.15%
  • Cardinal Health (NYSE:CAH) +52.51%
  • Nucor (NYSE:NUE) +62.35%
  • Haemonetics (NYSE:HAE) +49.21%

Asian holdings such as Dian Swastatika (IDX:DSSA) +69.14%, Kingboard Chem (SEHK:148) +65.65%, and Tokyo Electron (TSE:8035) +35.21% also posted strong June returns.

Triple‑Digit Gains

Several positions have exceeded 100% appreciation since selection:

  • Kingboard Chem (SEHK:148) +505.05%
  • Nordex SE (XTRA:NDX1) +205.34%
  • ASE Industrial (TWSE:3711) +162.81%
  • MediaTek (TWSE:2454) +185.32%
  • Dogu Aras Enerji Yatirimlari AS (IBSE:ARASE) +117.89%
  • Lenovo Group (SEHK:992) +150.72%

Upcoming July Rebalance

A new list of AI‑generated picks for July will be published in two days. Current members can view the June portfolio and its rationale before the July rebalance; non‑members are invited to subscribe via the app or web.

Subscription Pricing

Access to the AI‑selected portfolio and underlying research is offered for less than $9 per month.

AI Selection Methodology

The ProPicks engine evaluates over 60,000 global equities using more than 150 quantitative models that incorporate 15 years of historical financial data, valuation signals, and forward‑looking growth metrics. Each month up to 20 high‑conviction stocks are selected per strategy, weighted equally, and the portfolio is rebalanced monthly.

Illustrative Stock Analyses

  • Amneal Pharmaceuticals: June gain of +33.57% was driven by FDA approval of a romidepsin cancer therapy and positive Parkinson’s trial results. Prior to June, the stock had delivered ~80% return over the past year, gross margins expanded by 500 bps YoY toward ~45%, adjusted EBITDA rose 19% in Q1 2026, and a PEG ratio of 0.04 indicated deep valuation discount. The company’s acquisition of Kashiv BioSciences targets a $100 billion biosimilar market with revenue goals of $4.3‑$4.5 billion by 2030.
  • Molina Healthcare: Up +25.37% in June and +69.15% since April selection. The stock traded at roughly 37% of its 52‑week high, with analyst targets of $150‑$195 versus a $133 entry price. Total revenue grew ~11% to over $43 billion, with $9 billion of potential new Medicaid contracts identified. Management expects earnings power of $11 per share in 2025, and the balance sheet is cash‑rich with a “GREAT” financial health rating.
  • Asana: Added in April at $6.33, sold at $9.07 for a 43.3% gain before a 23% price decline. The exit was triggered by a 57% decline over the past year, valuation stretch (price‑to‑book ~13x) and cash pressure from stock‑based compensation and a $75 million acquisition, despite 89% gross margins and AI product adoption ahead of targets.

Access Options

Members can view the full June pick list and rationale via provided links; prospective subscribers are directed to app and web subscription pages.